[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637666":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":58,"collaborators":19,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":19,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":19,"enrollmentInfo":70,"targetDuration":19,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Synusight Biotech (Shanghai) Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SST001","EXPERIMENTAL","Administration of SST001",[13],"Drug: SST001",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Participants will undergo PET imaging after administration.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Jian Wang, Professor","CONTACT","+86 021-52888163","wangjian336@hotmail.com",[27,46],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Affiliated Hospital of Jiangnan University","RECRUITING","Wuxi","Jiangsu","214122","China","CN",{"type":36,"coordinates":37},"Point",[38,39],120.28857,31.56887,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":44,"phoneExt":19,"email":45},"Jing Chun Yu, Professor","+86 0510-68089401","ycjwxd1978@jiangnan.edu.cn",{"facility":47,"status":29,"city":48,"state":49,"zip":50,"country":33,"countryCode":34,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Huashan Hospital, Fudan University","Shanghai","Shanghai Municipality","200040",{"type":36,"coordinates":52},[53,54],121.45806,31.22222,{"lat":54,"lon":53},[57],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":59,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100637666","phase-1-a-study-to-evaluate-satety-tolerability-biodistribution-radiation-dosimetry-and-pharmacokinetics-of-sst001-in-healthy-volunteers-patients-with-pd-and-patients-with-msa-100637666",false,"NCT07604116","A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA","A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Sign the informed consent form approved by IEC.\n* Male or female participants aged ≥40 years old.\n* Adequate organ functions.\n* Proper contraception methods.\n* Willingness to follow the study procedures.\n* Additional inclusion criteria for healthy volunteers: Good health status; no history of motor disorders or cognitive disorders.\n* Additional inclusion criteria for MSA: Diagnosed with clinically established or clinically probable MSA according to the MDS MSA criteria (2022). If previously treated, the treatment regimen for MSA must have been stable for at least 4 weeks with no planned adjustments in the near term.\n* Additional inclusion criteria for PD: Diagnosed with clinically established or clinically probable PD according to the MDS PD criteria (2015). If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.\n\nExclusion Criteria:\n\n* Being pregnant or lactating.\n* History of other severe neurological disorders.\n* History of serious or uncontrolled medical condition.\n* Active HBV\u002FHCV\u002FHIV infection, etc.\n* History of abuse of drugs or alcohol within 1 year.\n* Allergy to the study drug.\n* Intolerance to PET\u002FCT or MRI (e.g. claustrophobia).\n* Any interventional clinical studies within 30 days.\n* Radiation exposure dose exceeding 50 mSv\u002Fyear.\n* Prior therapy targeting α-Syn.\n* Other ineligible conditions for this study.",true,"ALL","40 Years",{"count":71,"type":72},30,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.",[78,79],"Multiple System Atrophy (MSA)","Parkinson's Disease (PD)","2026-06-29",{"date":82,"type":83},"2026-06-30","ACTUAL",{"date":85,"type":83},"2026-06-15",{"date":87,"type":72},"2027-02",{"name":5,"class":6},2]